Yu-Feng Yang1, Ying-Yang Liao2, Xian-Lian Liu3, Shu-Guang Su4, Lin-Zhu Li5, Ning-Fu Peng6. 1. Department of Pathology, Dongguan Third People's Hospital, Dongguan, Guangdong Province, China. 2. Department of Surgical Oncology, the Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Province, China. 3. Department of Gynecology, Dongguan Third People's Hospital, Dongguan, Guangdong Province, China. 4. Department of Pathology, Panyu Maternal and Child Care Service Center of Guangzhou, Guangdong Province, China. 5. Department of Pathology, Gaoming District People's Hospital, Foshan, Guangdong Province, China. 6. Department of Surgical Oncology, the Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Province, China. Electronic address: pengnf2008@163.com.
Abstract
OBJECTIVE: To evaluate possible prognostic factors regarding regression and relapse of complex atypical hyperplasia (CAH) and well-differentiated endometrioid adenocarcinoma (WDC) treated with conservative treatment. METHODS: The retrospective study reviewed clinicopathologic, treatment, regression and relapse data from patients diagnosed with CAH or WDC who were treated with conservative treatment at 4 institutions. Potential factor evaluation was performed. SPSS 16 was used for statistical analyses. RESULTS: Eighty-eight patients were included (51 had WDC, and 37 had CAH). Regression was evaluated in 88 patients, with a median follow-up of 61 (range 15-95) months. Seventy-seven (87.5%) patients regressed, and 11 (12.5%) had persistent or progressive disease. Univariate and multivariate analyses showed no factors associated with regression. Relapse was evaluated in 71 patients, with median follow-up of 54 (range 8-86) months. Twenty-five/71 (35.2%) patients experienced relapse. On univariate analysis, body mass index (BMI) 30 or higher (p=0.001), WCD at initial biopsy (p=0.017) and positive expression of post-treatment ki67 (p=0.033) were associated to a higher relapse probability. However, only BMI 30 or higher was significant on multivariate analysis (p=0.012). The Kaplan-Meier analysis revealed a higher relapse probability in the patients with BMI 30 or higher (p=0.001). CONCLUSION: Obesity seems to be a risk factor for relapse of CAH or WDC with conservative treatment.
OBJECTIVE: To evaluate possible prognostic factors regarding regression and relapse of complex atypical hyperplasia (CAH) and well-differentiated endometrioid adenocarcinoma (WDC) treated with conservative treatment. METHODS: The retrospective study reviewed clinicopathologic, treatment, regression and relapse data from patients diagnosed with CAH or WDC who were treated with conservative treatment at 4 institutions. Potential factor evaluation was performed. SPSS 16 was used for statistical analyses. RESULTS: Eighty-eight patients were included (51 had WDC, and 37 had CAH). Regression was evaluated in 88 patients, with a median follow-up of 61 (range 15-95) months. Seventy-seven (87.5%) patients regressed, and 11 (12.5%) had persistent or progressive disease. Univariate and multivariate analyses showed no factors associated with regression. Relapse was evaluated in 71 patients, with median follow-up of 54 (range 8-86) months. Twenty-five/71 (35.2%) patients experienced relapse. On univariate analysis, body mass index (BMI) 30 or higher (p=0.001), WCD at initial biopsy (p=0.017) and positive expression of post-treatment ki67 (p=0.033) were associated to a higher relapse probability. However, only BMI 30 or higher was significant on multivariate analysis (p=0.012). The Kaplan-Meier analysis revealed a higher relapse probability in the patients with BMI 30 or higher (p=0.001). CONCLUSION: Obesity seems to be a risk factor for relapse of CAH or WDC with conservative treatment.
Authors: Pierluigi Giampaolino; Valeria Cafasso; Dominga Boccia; Mario Ascione; Antonio Mercorio; Francesco Viciglione; Mario Palumbo; Paolo Serafino; Cira Buonfantino; Maria Chiara De Angelis; Paolo Verrazzo; Giovanna Grasso; Giuseppe Gullo; Giuseppe Bifulco; Luigi Della Corte Journal: Biomed Res Int Date: 2022-09-27 Impact factor: 3.246